- Home
- SDOT vs APRE Comparison
SDOT vs APRE Comparison
Compare SDOT & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SDOT
- APRE
- Stock Information
- Founded
- SDOT 2014
- APRE 2006
- Country
- SDOT United States
- APRE United States
- Employees
- SDOT N/A
- APRE N/A
- Industry
- SDOT Restaurants
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SDOT Consumer Discretionary
- APRE Health Care
- Exchange
- SDOT Nasdaq
- APRE Nasdaq
- Market Cap
- SDOT 17.6M
- APRE 15.8M
- IPO Year
- SDOT 2020
- APRE 2019
- Fundamental
- Price
- SDOT $3.08
- APRE $4.01
- Analyst Decision
- SDOT Hold
- APRE Strong Buy
- Analyst Count
- SDOT 1
- APRE 2
- Target Price
- SDOT N/A
- APRE $15.50
- AVG Volume (30 Days)
- SDOT 44.4K
- APRE 35.2K
- Earning Date
- SDOT 11-12-2024
- APRE 11-07-2024
- Dividend Yield
- SDOT N/A
- APRE N/A
- EPS Growth
- SDOT N/A
- APRE N/A
- EPS
- SDOT 0.35
- APRE N/A
- Revenue
- SDOT $655,938,000.00
- APRE $1,310,839.00
- Revenue This Year
- SDOT $1.20
- APRE $134.21
- Revenue Next Year
- SDOT $29.55
- APRE N/A
- P/E Ratio
- SDOT $8.92
- APRE N/A
- Revenue Growth
- SDOT N/A
- APRE 130.31
- 52 Week Low
- SDOT $2.24
- APRE $2.15
- 52 Week High
- SDOT $7.00
- APRE $8.85
- Technical
- Relative Strength Index (RSI)
- SDOT 35.24
- APRE 59.23
- Support Level
- SDOT $3.26
- APRE $3.34
- Resistance Level
- SDOT $3.58
- APRE $4.41
- Average True Range (ATR)
- SDOT 0.32
- APRE 0.43
- MACD
- SDOT -0.07
- APRE 0.03
- Stochastic Oscillator
- SDOT 12.99
- APRE 44.69
About SDOT Sadot Group Inc.
Sadot Group Inc operates in the food supply chain sector, connecting producers and consumers across the globe, delivering agri-commodities from producing geographies such as the Americas, Africa, and the Black Sea to consumer markets in Southeast Asia, China, and the Middle East/North Africa (MENA) region. Its reportable segment includes Sadot food service and Sadot agri-foods. The key revenue is coming from the Sadot agri-foods segment which engaged in farming, commodity trading, and shipping of food and feed.
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline product is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.